Expression profile of Oct‑4 lung cancer‑specific marker prior and subsequent to a salirasib treatment regime

Ao,Xiang; Zhou,Jie; Liang,Hong  Ling; Jiang,Ming; Li,Hong  Sheng

doi:10.3892/ol.2017.6868

November-2017 Volume 14 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2017 Volume 14 Issue 5

Full Size Image

Article Open Access

Expression profile of Oct‑4 lung cancer‑specific marker prior and subsequent to a salirasib treatment regime

Authors:
- Xiang Ao
- Jie Zhou
- Hong Ling Liang
- Ming Jiang
- Hong Sheng Li
View Affiliations / Copyright

Affiliations: Department of Thoracic and Breast Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China

Copyright: © Ao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 5145-5148
|
Published online on: September 1, 2017

https://doi.org/10.3892/ol.2017.6868
Expand metrics +

Abstract

Lung cancer is one of the leading types of cancer that lead to mortalities in the male and female populations. The existing lung cancer‑specific markers are not able to accurately predict the condition of the disease, and the response of these markers can vary under various pathological conditions. The ability for tumors to regenerate following treatment can be more aggressive, and this may be due to the remaining lung cancer‑specific stem cells, which are resistant to chemotherapeutic drugs. Evaluating cancer stem cells under various pathological conditions, as well as prior and subsequent to treatment, can help to increase the understanding of the underlying mechanisms. In the present study, a mouse model with initial and advanced forms of lung cancer was developed using tobacco smoke carcinogen. It was observed from tissue sections that there were many actively dividing cells spread throughout the mouse lung tissue with the initial stages of lung cancer, and these cells aggregated in advanced stages of lung cancer. Furthermore, immunohistochemical staining indicated that there was an increased number of octamer‑binding protein 4 (Oct‑4)‑positive cells present in mouse tissues with advanced stages of the disease compared with tissues without lung cancer or at the initial stages of disease. The cancer stem cell population following salirasib treatment was also investigated in two groups. The mice in the early treatment group were administered with salirasib following 1 month of tumor growth, and the delayed treatment group was treated following 2 months of tumor growth. The number of cancer stem cells was markedly reduced in the early treatment group. However, salirasib failed to have any observable effect in the delayed treatment group. Cancer stem cells were analyzed using the marker Oct‑4 to improve an understanding of the proliferative ability of cancer stem cells under various pathological conditions, which may lead to the development of novel cancer therapeutics.

View Figures

View References

1	Larsen JE and Minna JD: Molecular biology of lung cancer: Clinical implications. Clinics Chest Med. 32:703–740. 2011. View Article : Google Scholar
2	Keshamouni V, Arenberg D and Kalemkerian G: Lung Cancer Metastasis. Springer; New York, NY: 2009
3	Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, Flanders WD, Jee SH, Katanoda K, Kolonel LN, et al: Lung cancer occurrence in never-smokers: An analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 5:e1852008. View Article : Google Scholar : PubMed/NCBI
4	Beckles MA, Spiro SG, Colice GL and Rudd RM: Initial evaluation of the patient with lung cancer: Symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 123 (1 Suppl):97S–104S. 2003. View Article : Google Scholar : PubMed/NCBI
5	Mumbarkar PP, Raste AS and Ghadge MS: Significance of tumor markers in lung cancer. Indian J Clin Biochem. 21:173–176. 2006. View Article : Google Scholar : PubMed/NCBI
6	Thunnissen FB: Sputum examination for early detection of lung cancer. J Clin Pathol. 56:805–810. 2003. View Article : Google Scholar : PubMed/NCBI
7	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
8	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
9	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
10	Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
11	Giangreco A, Groot KR and Janes SM: Lung cancer and lung stem cells: Strange bedfellows? Am J Respir Crit Care Med. 175:547–553. 2007. View Article : Google Scholar : PubMed/NCBI
12	Witschi H, Espiritu I, Maronpot RR, Pinkerton KE and Jones AD: The carcinogenic potential of the gas phase of environmental tobacco smoke. Carcinogenesis. 18:2035–2042. 1997. View Article : Google Scholar : PubMed/NCBI
13	Hamidouche Z, Haÿ E, Vaudin P, Charbord P, Schüle R, Marie PJ and Fromigué O: FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression. FASEB J. 22:3813–3822. 2008. View Article : Google Scholar : PubMed/NCBI
14	Heppner GH and Miller BE: Tumor heterogeneity: Biological implications and therapeutic consequences. Cancer Metastasis Rev. 2:5–23. 1983. View Article : Google Scholar : PubMed/NCBI
15	Wicha MS, Liu S and Dontu G: Cancer stem cells: An old idea - a paradigm shift. Cancer Res. 66:1883–1890. 2006. View Article : Google Scholar : PubMed/NCBI
16	Morgan G, Ward R and Barton M: The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 16:549–560. 2004. View Article : Google Scholar : PubMed/NCBI
17	Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C and Abken H: Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA. 108:2474–2479. 2011. View Article : Google Scholar : PubMed/NCBI
18	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar : PubMed/NCBI
19	Clark EA, Golub TR, Lander ES and Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 406:532–535. 2000. View Article : Google Scholar : PubMed/NCBI
20	Liotta LA, Kleinerman J and Saldel GM: The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 36:889–894. 1976.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Expression profile of Oct‑4 lung cancer‑specific marker prior and subsequent to a salirasib treatment regime

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles